From Lipase Elevation to Diabetes – Pancreatic Involvement during Immune Checkpoint Inhibition
Open Access
- 23 March 2023
- journal article
- research article
- Published by Scientific Archives
- Vol. 5 (1) , 14-18
Abstract
Nowadays, as a standard of care treatment of several cancers, immune checkpoint inhibitors have changed the field of oncology. However, their empowerment of T cellKeywords
This publication has 21 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Pancreatic involvement due to immune checkpoint inhibitors: a proposed classificationCancer Immunology, Immunotherapy, 2022
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysisThe Lancet Oncology, 2021
- Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology GroupEuropean Journal of Cancer, 2021
- The multifaceted nature of diabetes mellitus induced by checkpoint inhibitorsActa Diabetologica, 2019
- Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysisPancreatology, 2019
- Diarrhoea during checkpoint blockade, not always colitisEuropean Journal of Cancer, 2017
- Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactionsCancer Treatment Reviews, 2017
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- Day-to-Day Variations of Serum Pancreatic Enzymes in Benign Pancreatic HyperenzymemiaClinical Gastroenterology and Hepatology, 2007